Evidence map›Paper›PMID 40722116›Full record

Observational studyArthritis research & therapy2025

Type II diabetes in systemic sclerosis patients: insights from an observational, multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale).

Vasiliki Liakouli, Giulio Forte, Piero Ruscitti, Luca Navarini, Francesca Bellisai, Francesco Caso, Giuliana Guggino, Lidia La Barbera, Chiara Rizzo, Ada Corrado and 13 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Vasiliki LiakouliRheumatology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, Italy. vasiliki.liakouli@unicampania.it.
Giulio ForteRheumatology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, Italy.
Piero RuscittiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Luca NavariniClinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico, Rome, Italy.
Francesca BellisaiRheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena, Italy.
Francesco CasoRheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.
Giuliana GugginoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology section, University of Palermo, Palermo, Italy.
Lidia La BarberaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology section, University of Palermo, Palermo, Italy.
Chiara RizzoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology section, University of Palermo, Palermo, Italy.
Ada CorradoRheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Paola TriggianeseDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Alberto Lo GulloRheumatology Unit, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy.
Giuseppe MandraffinoInternal Medicine Unit, University Hospital G. Martino, University of Messina, Messina, Italy.
Luca CantariniRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Bruno FredianiRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Paola CiprianiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Francesco Paolo CantatoreRheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Maria Sole ChimentiRheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
Elvira FavoinoRheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine (DIM), University of Bari Medical School, Bari, Italy.
Federico PerosaRheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine (DIM), University of Bari Medical School, Bari, Italy.
Annamaria IagnoccoAcademic Rheumatology Centre, Department of Clinical and Biological Science, Hospital Mauriziano, University of Turin, Turin, Italy.
Roberto GiacomelliClinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico, Rome, Italy.
Francesco CicciaRheumatology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the contribution of Systemic sclerosis (SSc)-specific features on type II diabetes mellitus (T2D) in a large cohort of Italian SSc patients.

methodsA total of 613 SSc patients from 11 tertiary Rheumatology Units across Italy were included. All patients underwent full history taking, clinical examination, and relevant laboratory and radiological evaluations. Demographic, socioeconomic, and disease-specific factors were compared between SSc patients with and without T2D.

resultsThe prevalence of T2D in the study cohort was 7.6%. SSc patients with T2D were significantly older (P < 0.007) and exhibited: higher prevalence of late-stage capillaroscopic pattern (P < 0.001), severe reduction in forced vital capacity (FVC < 50%; P < 0.000), moderate reduction in total lung capacity (TLC 50-69%; P < 0.011), electrocardiographic signs of right ventricular hypertrophy (P < 0.018), higher prevalence of pulmonary arterial hypertension (PAH) confirmed by right heart catheterization (RHC) (P < 0.037) and higher prevalence scleroderma renal crisis (SRC) (P < 0.001); elevated erythrocyte sedimentation rate (ESR) (P < 0.022), and ANA positivity. These patients more frequently assumed angiotensin-converting enzyme inhibitors (ACEi) (P < 0.005) when compared to their non-T2D counterparts, while the use of immunosuppressive therapies was similar between groups. Multivariate analysis identified older age, SRC, and reductions in both TLC and FVC as independent SSc-specific associated factors of T2D.

conclusionAlthough the prevalence of T2D in SSc patients is lower than the global estimates reported by the International Federation of Diabetes (IFD), a distinct subgroup of SSc patients with T2D is characterized by unique disease manifestations and complications, including SRC and impaired lung function. These findings underscore the importance of tailored screening and management approaches to address the intersecting metabolic and vascular risks in this population.

Indexed as

Diabetes Mellitus, Type 2Scleroderma, SystemicAdultAgedCohort StudiesFemaleHumansItalyMaleMiddle AgedPrevalenceRheumatologyDiabetes mellitus type IIImpaired fasting glucoseSystemic sclerosisTraditional cardiovascular risk factors

Identifiers

PMID40722116
PMCPMC12306082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.